Cargando…
Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis
Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along with a history of systemic mastocytosis who developed evidence of an autoimmune enteropathy shortly after ini...
Autores principales: | Lakritz, Stephanie, Forsberg, Peter A., Sherbenou, Daniel W., Mark, Tomer M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483819/ https://www.ncbi.nlm.nih.gov/pubmed/36188028 http://dx.doi.org/10.1002/ccr3.6199 |
Ejemplares similares
-
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
por: Keller, Alana L., et al.
Publicado: (2022) -
309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022) -
Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma
por: Zanelli, Magda, et al.
Publicado: (2021) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018) -
CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts
por: VanWyngarden, Michael J., et al.
Publicado: (2023)